JPWO2022216762A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022216762A5 JPWO2022216762A5 JP2023561271A JP2023561271A JPWO2022216762A5 JP WO2022216762 A5 JPWO2022216762 A5 JP WO2022216762A5 JP 2023561271 A JP2023561271 A JP 2023561271A JP 2023561271 A JP2023561271 A JP 2023561271A JP WO2022216762 A5 JPWO2022216762 A5 JP WO2022216762A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- alkyl
- halogen
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 229910052736 halogen Inorganic materials 0.000 claims 27
- 150000002367 halogens Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 15
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 14
- 150000002431 hydrogen Chemical group 0.000 claims 11
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000001118 alkylidene group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- 206010069755 K-ras gene mutation Diseases 0.000 claims 2
- 101150105104 Kras gene Proteins 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- -1 pyrrolopyridinyl Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000005494 pyridonyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 102200006531 rs121913529 Human genes 0.000 claims 1
- 102200006539 rs121913529 Human genes 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000002053 thietanyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021085959 | 2021-04-08 | ||
| CNPCT/CN2021/085959 | 2021-04-08 | ||
| PCT/US2022/023573 WO2022216762A1 (en) | 2021-04-08 | 2022-04-06 | Oxazepine compounds and uses thereof in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024513881A JP2024513881A (ja) | 2024-03-27 |
| JP2024513881A5 JP2024513881A5 (https=) | 2025-04-02 |
| JPWO2022216762A5 true JPWO2022216762A5 (https=) | 2025-04-02 |
Family
ID=81387302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561271A Pending JP2024513881A (ja) | 2021-04-08 | 2022-04-06 | オキサゼピン化合物及びがんの治療におけるその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240383915A1 (https=) |
| EP (1) | EP4320132A1 (https=) |
| JP (1) | JP2024513881A (https=) |
| KR (1) | KR20230167386A (https=) |
| CN (1) | CN117083279A (https=) |
| AR (1) | AR125304A1 (https=) |
| AU (1) | AU2022254674A1 (https=) |
| BR (1) | BR112023020773A2 (https=) |
| CA (1) | CA3215949A1 (https=) |
| MX (1) | MX2023011873A (https=) |
| TW (1) | TWI868441B (https=) |
| WO (1) | WO2022216762A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| KR20240163107A (ko) | 2022-03-11 | 2024-11-18 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CA3261681A1 (en) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| AU2023320914A1 (en) * | 2022-08-11 | 2025-02-27 | Beone Medicines I Gmbh | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2024041573A1 (en) * | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| JP2025535294A (ja) * | 2022-10-18 | 2025-10-24 | アイディーエンス カンパニー リミテッド | 新規なトリヘテロ環化合物 |
| JP2025535367A (ja) * | 2022-10-19 | 2025-10-24 | ジェネンテック， インコーポレイテッド | ６－アザ部分を含むオキサゼピン化合物およびその使用 |
| WO2024112654A1 (en) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2024153180A1 (zh) * | 2023-01-18 | 2024-07-25 | 上海艾力斯医药科技股份有限公司 | 杂环类化合物、其药物组合物及其用途 |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| WO2024197503A1 (en) * | 2023-03-27 | 2024-10-03 | Nikang Therapeutics , Inc. | Tricyclic derivatives as kras inhibitors |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| EP4713330A1 (en) * | 2023-05-16 | 2026-03-25 | HUTCHMED Limited | Tricyclic compounds and uses thereof |
| CN121605110A (zh) * | 2023-06-06 | 2026-03-03 | 金橘生物科技公司 | 取代杂环化合物及其用途 |
| AU2024307234A1 (en) * | 2023-06-30 | 2026-01-29 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| CN116903499B (zh) * | 2023-07-11 | 2025-05-30 | 上海应用技术大学 | 无水氟磺酰基二氟乙酸铜盐及其制备方法与应用 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| AU2024323424A1 (en) | 2023-08-17 | 2026-03-05 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250163079A1 (en) * | 2023-11-01 | 2025-05-22 | Incyte Corporation | Kras inhibitors |
| WO2025111586A1 (en) | 2023-11-22 | 2025-05-30 | Genentech, Inc. | Polymorphs of and synthetic process for an aza-tetracyclic oxazepine inhibitor of kras-g12d |
| TW202527946A (zh) * | 2023-12-19 | 2025-07-16 | 大陸商正大天晴藥業集團股份有限公司 | 三并環類化合物及其醫藥用途 |
| WO2025167948A1 (zh) * | 2024-02-06 | 2025-08-14 | 上海齐鲁制药研究中心有限公司 | 嘧啶并大环类kras抑制剂 |
| WO2025168072A1 (en) * | 2024-02-08 | 2025-08-14 | Beigene (Suzhou) Co., Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| CR20190157A (es) * | 2016-08-31 | 2019-08-13 | Agios Pharmaceuticals Inc | Inhibidores de procesos metabólicos celulares |
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| ES3010507T3 (en) * | 2019-03-05 | 2025-04-03 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| WO2021063346A1 (zh) * | 2019-09-30 | 2021-04-08 | 上海迪诺医药科技有限公司 | Kras g12c抑制剂及其应用 |
-
2022
- 2022-04-06 WO PCT/US2022/023573 patent/WO2022216762A1/en not_active Ceased
- 2022-04-06 MX MX2023011873A patent/MX2023011873A/es unknown
- 2022-04-06 EP EP22719149.1A patent/EP4320132A1/en active Pending
- 2022-04-06 JP JP2023561271A patent/JP2024513881A/ja active Pending
- 2022-04-06 BR BR112023020773A patent/BR112023020773A2/pt unknown
- 2022-04-06 TW TW111113063A patent/TWI868441B/zh active
- 2022-04-06 US US18/554,438 patent/US20240383915A1/en active Pending
- 2022-04-06 CN CN202280026974.XA patent/CN117083279A/zh active Pending
- 2022-04-06 AR ARP220100858A patent/AR125304A1/es unknown
- 2022-04-06 AU AU2022254674A patent/AU2022254674A1/en active Pending
- 2022-04-06 CA CA3215949A patent/CA3215949A1/en active Pending
- 2022-04-06 KR KR1020237037698A patent/KR20230167386A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022216762A5 (https=) | ||
| US6545020B1 (en) | Farnesyl Protein transferase inhibitors with in vivo radiosensitizing properties | |
| ES2261476T3 (es) | Derivados de quinolina y quinazolina que inhiben la farnesil-tranferasa como inhibidores de farnesil-tranferasa. | |
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JPWO2022173678A5 (https=) | ||
| JP2019526615A5 (https=) | ||
| CA2585053A1 (en) | Substituted n-acyl (hetero)aryl compounds as c-fms kinase inhibitors | |
| RU2005116689A (ru) | Средство для профилактики или лечения невропатии | |
| JP2011515462A5 (https=) | ||
| JP2021516240A5 (https=) | ||
| JP2006509715A5 (https=) | ||
| JP2004520402A (ja) | Ｅｒｋ２の複素環式インヒビターおよびその使用 | |
| JP2010529991A5 (https=) | ||
| CA2397558A1 (en) | Dosing regimen | |
| RU2006127572A (ru) | Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата | |
| RU2001131104A (ru) | Новые производные бензимидазола и содержащие эти соединения фармацевтические композиции | |
| AU2003275364A1 (en) | Synergistic methods and compositions for treating cancer | |
| JP2008517945A5 (https=) | ||
| JP2007513969A5 (https=) | ||
| CA2366857A1 (en) | Phthalazine derivatives for treating inflammatory diseases | |
| CA2434813A1 (en) | Imidazole derivatives | |
| JP2006507247A5 (https=) | ||
| JP2018507235A (ja) | ステロール調節エレメント結合タンパク質（ｓｒｅｂｐ）阻害剤 | |
| TW201920153A (zh) | 具有環狀構造的化合物 | |
| JPWO2019148044A5 (https=) |